TY - JOUR AU - Jemal, A. AU - Bray, F. AU - Center, M. M. AU - Ferlay, J. AU - Ward, E. AU - Forman, D. PY - 2011 DA - 2011// TI - Global cancer statistics JO - CA Cancer J Clin VL - 61 UR - https://doi.org/10.3322/caac.20107 DO - 10.3322/caac.20107 ID - Jemal2011 ER - TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2018 DA - 2018// JO - Cancer statistics, 2018 VL - 68 ID - Siegel2018 ER - TY - JOUR AU - Lu, J. AU - Han, B. H. PY - 2018 DA - 2018// TI - Liquid biopsy promotes non-small cell Lung Cancer precision therapy JO - Technol Cancer Res T VL - 7 ID - Lu2018 ER - TY - JOUR AU - Ettinger, D. S. AU - Wood, D. E. AU - Aisner, D. L. AU - Akerley, W. AU - Bauman, J. AU - Chirieac, L. R. PY - 2017 DA - 2017// TI - Non–small cell Lung Cancer, version 5.2017, NCCN clinical practice guidelines in oncology JO - J Natl Compr Canc Net VL - 15 UR - https://doi.org/10.6004/jnccn.2017.0050 DO - 10.6004/jnccn.2017.0050 ID - Ettinger2017 ER - TY - JOUR AU - Ettinger, D. S. AU - Wood, D. E. AU - Akerley, W. AU - Bazhenova, L. A. AU - Borghaei, H. AU - Camidge, D. R. PY - 2016 DA - 2016// TI - NCCN guidelines insights: non-small cell Lung Cancer, version 4.2016 JO - J Natl Compr Canc Net VL - 14 UR - https://doi.org/10.6004/jnccn.2016.0031 DO - 10.6004/jnccn.2016.0031 ID - Ettinger2016 ER - TY - JOUR AU - Sun, Y. AU - Niu, W. AU - Du, F. AU - Du, C. AU - Li, S. AU - Wang, J. PY - 2016 DA - 2016// TI - Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0332-8 DO - 10.1186/s13045-016-0332-8 ID - Sun2016 ER - TY - JOUR AU - Lin, B. AU - Song, X. AU - Yang, D. AU - Bai, D. AU - Yao, Y. AU - Lu, N. PY - 2018 DA - 2018// TI - Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1 JO - Gene VL - 654 UR - https://doi.org/10.1016/j.gene.2018.02.026 DO - 10.1016/j.gene.2018.02.026 ID - Lin2018 ER - TY - JOUR AU - Xie, C. AU - Wan, X. AU - Quan, H. AU - Zheng, M. AU - Fu, L. AU - Li, Y. AU - Lou, L. PY - 2018 DA - 2018// TI - Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor JO - Cancer Sci VL - 109 UR - https://doi.org/10.1111/cas.13536 DO - 10.1111/cas.13536 ID - Xie2018 ER - TY - STD TI - Han BH, Li K, Zhao YZ, Li BL, Cheng Y, Zhou JY, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018. https://doi.org/10.1038/bjc.2017.478. ID - ref9 ER - TY - JOUR AU - Han, B. H. AU - Li, K. AU - Wang, Q. M. AU - Zhao, Y. Z. AU - Zhang, L. AU - Shi, J. H. PY - 2017 DA - 2017// TI - Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30759-3 DO - 10.1016/S1470-2045(17)30759-3 ID - Han2017 ER - TY - STD TI - Han BH, Li K, Wang QM, Zhang L, Shi JH, Wang ZH, Cheng Y, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2018. https://doi.org/10.1001/jamaoncol.2018.3039. ID - ref11 ER - TY - JOUR AU - Camidge, D. R. AU - Pao, W. AU - Sequist, L. V. PY - 2014 DA - 2014// TI - Acquired resistance to TKIs in solid tumours: learning from lung cancer JO - Nat Rev Clin Oncol VL - 11 UR - https://doi.org/10.1038/nrclinonc.2014.104 DO - 10.1038/nrclinonc.2014.104 ID - Camidge2014 ER - TY - JOUR AU - Gerber, N. K. AU - Yamada, Y. AU - Rimner, A. AU - Shi, W. J. AU - Riely, G. J. AU - Beal, K. PY - 2014 DA - 2014// TI - Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant Lung adenocarcinoma JO - Int J Radiat Oncol VL - 89 UR - https://doi.org/10.1016/j.ijrobp.2014.02.022 DO - 10.1016/j.ijrobp.2014.02.022 ID - Gerber2014 ER - TY - JOUR AU - Mok, T. S. AU - Wu, Y. L. AU - Thongprasert, S. AU - Yang, C. H. AU - Chu, D. T. AU - Saijo, N. AU - Sunpaweravong, P. PY - 2009 DA - 2009// TI - Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0810699 DO - 10.1056/NEJMoa0810699 ID - Mok2009 ER - TY - JOUR AU - Shih, J. Y. AU - Gow, C. H. AU - Yang, P. C. PY - 2005 DA - 2005// TI - EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJM200507143530217 DO - 10.1056/NEJM200507143530217 ID - Shih2005 ER - TY - JOUR AU - Jakobsen, K. R. AU - Demuth, C. AU - Madsen, A. T. AU - Hussmann, D. AU - Vad-Nielsen, J. AU - Nielsen, A. L. PY - 2017 DA - 2017// TI - MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells JO - Oncogenesis VL - 6 UR - https://doi.org/10.1038/oncsis.2017.17 DO - 10.1038/oncsis.2017.17 ID - Jakobsen2017 ER - TY - JOUR AU - Joseph, N. A. AU - Chiou, S. H. AU - Lung, Z. AU - Yang, C. L. AU - Lin, T. Y. AU - Chang, H. W. PY - 2018 DA - 2018// TI - The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR resistance and epithelial-to-mesenchymal transition of lung adenocarcinoma cells JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0557-9 DO - 10.1186/s13045-018-0557-9 ID - Joseph2018 ER - TY - STD TI - Parra HJS, Noto L, Galetta D, Ferrau F, Gebbia V, Tassone P, et al. A phase II, noncomparative, open label, multicentre, study of AZD9291 in patients with locally advanced or metastatic EGFR mutated “T790M undetectable or unknown” non-small cell lung cancer (stage IIB-IV) after no immediate prior EGFR TKI (OSIRIS study). J Clin Oncol. 2017;35(15_suppl):TPS9107. ID - ref18 ER - TY - JOUR AU - Ku, B. M. AU - Bae, Y. H. AU - Koh, J. AU - Sun, J. M. AU - Lee, S. H. AU - Ahn, J. S. PY - 2016 DA - 2016// TI - AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR (L858R/T790M) in non-small cell lung cancer cells JO - Invest New Drug VL - 34 UR - https://doi.org/10.1007/s10637-016-0350-y DO - 10.1007/s10637-016-0350-y ID - Ku2016 ER - TY - JOUR AU - Vallee, A. AU - Audigier-Valette, C. AU - Herbreteau, G. AU - Merrien, J. AU - Tessonnier, L. AU - Theoleyre, S. PY - 2016 DA - 2016// TI - Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation JO - Lung Cancer VL - 91 UR - https://doi.org/10.1016/j.lungcan.2015.11.008 DO - 10.1016/j.lungcan.2015.11.008 ID - Vallee2016 ER - TY - JOUR AU - Engelman, J. A. AU - Zejnullahu, K. AU - Mitsudomi, T. AU - Song, Y. C. AU - Hyland, C. AU - Park, J. O. PY - 2007 DA - 2007// TI - MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling JO - Science VL - 316 UR - https://doi.org/10.1126/science.1141478 DO - 10.1126/science.1141478 ID - Engelman2007 ER - TY - JOUR AU - Uchibori, K. AU - Inase, N. AU - Nishio, M. AU - Fujita, N. AU - Katayama, R. PY - 2018 DA - 2018// TI - Identification of mutation accumulation as resistance mechanism emerging in first-line Osimertinib treatment JO - J Thorac Oncol VL - 13 UR - https://doi.org/10.1016/j.jtho.2018.04.005 DO - 10.1016/j.jtho.2018.04.005 ID - Uchibori2018 ER - TY - JOUR AU - Lu, J. AU - Chen, J. AU - Xu, N. AU - Wu, J. AU - Kang, Y. AU - Shen, T. AU - Kong, H. PY - 2016 DA - 2016// TI - Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress JO - Toxicol Lett VL - 258 UR - https://doi.org/10.1016/j.toxlet.2016.07.002 DO - 10.1016/j.toxlet.2016.07.002 ID - Lu2016 ER - TY - JOUR AU - Zhang, X. L. AU - Wu, J. AU - Wang, J. AU - Shen, T. AU - Li, H. AU - Lu, J. PY - 2016 DA - 2016// TI - Integrative epigenomic analysis reveals unique epigenetic signatures involved in unipotency of mouse female germline stem cells JO - Genome Biol VL - 17 UR - https://doi.org/10.1186/s13059-016-1023-z DO - 10.1186/s13059-016-1023-z ID - Zhang2016 ER - TY - STD TI - Lu J, Chen J, Kang Y, Wu J, Shi H, Fu Y, et al. Jinfukang induces cellular apoptosis through activation of Fas and DR4 in A549 cells. Oncol Lett. 2018. https://doi.org/10.3892/ol.2018.9149. ID - ref25 ER - TY - JOUR AU - Trapnell, C. AU - Roberts, A. AU - Goff, L. AU - Pertea, G. AU - Kim, D. AU - Kelley, D. R. PY - 2012 DA - 2012// TI - Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and cufflinks JO - Nat Protoc VL - 7 UR - https://doi.org/10.1038/nprot.2012.016 DO - 10.1038/nprot.2012.016 ID - Trapnell2012 ER - TY - STD TI - Lu J, Zhang X, Shen T, Ma C, Wu J, Kong H, et al. Epigenetic profiling of H3K4Me3 reveals herbal medicine Jinfukang-induced epigenetic alteration is involved in anti-Lung Cancer activity. Evid Based Complement Alternat Med. 2016. https://doi.org/10.1155/2016/7276161. ID - ref27 ER - TY - JOUR AU - Dennis, G. AU - Sherman, B. T. AU - Hosack, D. A. AU - Yang, J. AU - Gao, W. AU - Lane, H. C. PY - 2003 DA - 2003// TI - DAVID: database for annotation, visualization, and integrated discovery JO - Genome Biol VL - 4 UR - https://doi.org/10.1186/gb-2003-4-5-p3 DO - 10.1186/gb-2003-4-5-p3 ID - Dennis2003 ER - TY - JOUR AU - Mi, H. Y. AU - Muruganujan, A. AU - Casagrande, J. T. AU - Thomas, P. D. PY - 2013 DA - 2013// TI - Large-scale gene function analysis with the PANTHER classification system JO - Nat Protoc VL - 8 UR - https://doi.org/10.1038/nprot.2013.092 DO - 10.1038/nprot.2013.092 ID - Mi2013 ER - TY - JOUR AU - Han, J. AU - Jun, Y. AU - Kim, S. H. AU - Hoang, H. H. AU - Jung, Y. AU - Kim, S. PY - 2016 DA - 2016// TI - Rapid emergence and mechanisms of resistance by U87 glioblastoma cells to doxorubicin in an in vitro tumor microfluidic ecology JO - Proc Natl Acad Sci U S A VL - 113 UR - https://doi.org/10.1073/pnas.1614898113 DO - 10.1073/pnas.1614898113 ID - Han2016 ER - TY - JOUR AU - Jia, D. Y. AU - Li, L. AU - Andrew, S. AU - Allan, D. AU - Li, X. G. AU - Lee, J. PY - 2017 DA - 2017// TI - An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells JO - Cell Death Dis VL - 8 UR - https://doi.org/10.1038/cddis.2017.319 DO - 10.1038/cddis.2017.319 ID - Jia2017 ER - TY - JOUR AU - Porras, V. R. AU - Bystrup, S. AU - Martínez-Cardús, A. AU - Pluvinet, R. AU - Sumoy, L. AU - Howells, L. PY - 2016 DA - 2016// TI - Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-chemokine/NF-κB signalling pathway JO - Sci Rep VL - 6 UR - https://doi.org/10.1038/srep24675 DO - 10.1038/srep24675 ID - Porras2016 ER - TY - JOUR AU - Song, X. F. AU - Wang, Z. AU - Jin, Y. AU - Wang, Y. AU - Duan, W. B. PY - 2015 DA - 2015// TI - Loss of miR-532-5p in vitro promotes cell proliferation and metastasis by influencing CXCL2 expression in HCC JO - Am J Transl Res VL - 7 ID - Song2015 ER - TY - JOUR AU - Gao, Y. AU - Guan, Z. F. AU - Chen, J. Q. AU - Xie, H. J. AU - Yang, Z. AU - Fan, J. H. PY - 2015 DA - 2015// TI - CXCL5/CXCR2 axis promotes bladder cancer cell migration and invasion by activating PI3K/AKT-induced upregulation of MMP2/MMP9 JO - Int J Oncol VL - 47 UR - https://doi.org/10.3892/ijo.2015.3041 DO - 10.3892/ijo.2015.3041 ID - Gao2015 ER - TY - STD TI - Lu J, Zhong H, Chu T, Zhang XY, Li R, Sun JY, et al. Role of anlotinib-induced CCL2 decrease in antiangiogenesis and response prediction for non-small cell lung cancer therapy. Eur Respir J. 2018. https://doi.org/10.1183/13993003.01562-2018 ID - ref35 ER - TY - JOUR AU - Paez, J. G. AU - Janne, P. A. AU - Lee, J. C. AU - Tracy, S. AU - Greulich, H. AU - Gabriel, S. PY - 2004 DA - 2004// TI - EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy JO - Science VL - 304 UR - https://doi.org/10.1126/science.1099314 DO - 10.1126/science.1099314 ID - Paez2004 ER - TY - JOUR AU - Collisson, E. A. AU - Campbell, J. D. AU - Brooks, A. N. AU - Berger, A. H. AU - Lee, W. AU - Chmielecki, J. PY - 2014 DA - 2014// TI - Comprehensive molecular profiling of lung adenocarcinoma JO - Nature VL - 511 UR - https://doi.org/10.1038/nature13385 DO - 10.1038/nature13385 ID - Collisson2014 ER - TY - JOUR AU - Al-Alwan, L. A. AU - Chang, Y. AU - Mogas, A. AU - Halayko, A. J. AU - Baglole, C. J. AU - Martin, J. G. PY - 2013 DA - 2013// TI - Differential roles of CXCL2 and CXCL3 and their receptors in regulating normal and asthmatic airway smooth muscle cell migration JO - J Immunol VL - 191 UR - https://doi.org/10.4049/jimmunol.1203421 DO - 10.4049/jimmunol.1203421 ID - Al-Alwan2013 ER -